Exogenous oestrogen inhibits genital transmission of cell-associated HIV-1 in DMPA-treated humanized mice
HIV affects more women than any other life-threatening infectious agent, and most infections are sexually transmitted. HIV must breach the female genital tract mucosal barrier to establish systemic infection, and clinical studies indicate virus more easily evades this barrier in women using depot-medroxyprogesterone acetate (DMPA) and other injectable progestins for contraception.
Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial
Background Evidence from observational studies suggests an increased risk of HIV acquisition among women using depot medroxyprogesterone acetate (DMPA) contraception.
AVAC, in collaboration with ICW East Africa, is pleased to invite you to a webinar on the most recent data regarding hormonal contraception and HIV. We hope you will join us on Friday, September 16 at 10 AM East Coast US / 4 PM South Africa / 5 PM East Africa (to confirm the time in your area visit www.timeanddate.com).
Over the years studies have produced conflicting evidence about the link between hormonal contraception – especially DMPA, a long-acting progesterone-only injectable – and women's risk of HIV infection.